Risk Stratification

Combination Testing With ThyGeNEXT and ThyraMIR Provides Accurate Reclassification1

ThyGeNEXT + ThyraMIR Combination Testing Performance1

High NPV

  • Significant decrease in unnecessary surgeries
  • 85% reduction relative to cytology alone (P<0.01)

Testing helps to risk-stratify the need for or extent of surgery needed

ATA and NCCN Guidelines support testing for nodules with a B-III or B-IV cytology diagnosis

50 %
Sensitivity
50 %
NPV
50 %
Specificity
40 %
PPV

Markers

Strategically Designed Panel for the Optimal Management of Thyroid Nodules

ThyGeNEXT® NGS PanelThyraMIR® miRNA classifier
DNA mutation panelRNA panel (# fusions)
ALKALK (2)miR-29b-1-5p
BRAFBRAF (2)miR-31-5p
GNASNTRK (8)miR-138-1-3p
HRASPPARg (6)miR-139-5p
KRASRET (14)miR-146b-5p
NRASTHADA (5)miR-155
PIK3CAmRNA controls:
NKX2-1, PAX8, TBP, USP33
miR-204-5p
PTENmiR-222-3p
RETmiR-375
TERTmiR-551b-3p

Newly added TERT and ALK mutations can reliably help to predict aggressive biological features of thyroid cancer, including:

  • Large tumor size
  • Higher patient mortality
  • Likelihood of lymph node metastasis
  • Higher rate of recurrence post-treatment
  • Higher clinical stage at time of cancer detection
  • Likelihood of cancer spreading beyond the thyroid
  • Increased risk for tumor vascular invasion
  • Potential for treatment failure

Long-Term Evidence

Impact of BRAF V600E or TERT C288T Alone or Their Coexistence on Disease-free Survival of Patients With PTC2

Coexisting BRAF V600E and TERT C228T mutations form a novel genetic background that defines PTC with the potentially worst clinicopathologic outcomes, providing unique prognostic and therapeutic implications.

References

  1. Labourier, et al, Journal Clinical Endocrinology Metabolism 100: 2743, 2015
  2. Xing M et al., BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence, Journal of Clinical Oncology 2014
Scroll to Top